Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

BMO Capital Upgrades Sarepta Therapeutics to Outperform, Maintains Price Target to $50

Author: Benzinga Newsdesk | September 22, 2025 07:21am
BMO Capital analyst Kostas Biliouris upgrades Sarepta Therapeutics (NASDAQ:SRPT) from Market Perform to Outperform and maintains the price target from $50 to $50.

Posted In: SRPT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist